US Airways Is on a ...
Health Care: Drugs
Synta Pharmaceuticals Inc. (SNTA: NASDAQ)
$7.66 0.15 | 2.00%
05/22/13 - 11:15 AM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 81.51M | 30.08M | 31.31M | 44.16M |
| Receivables | 0.00 | 0.00 | 116.00K | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 101.38M | 40.29M | 51.52M | 44.57M |
| Property, Plant & Equipment, Gross | 21.27M | 20.76M | 20.14M | 20.01M |
| Accumulated Depreciation & Depletion | 20.10M | 19.36M | 17.96M | 16.03M |
| Property, Plant & Equipment, Net | 1.17M | 1.41M | 2.18M | 3.98M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 458.00K | 631.00K | 366.00K | 358.00K |
| Total Non-Current Assets | 1.63M | 2.04M | 2.55M | 4.34M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 103.02M | 42.32M | 54.07M | 48.91M |
| Accounts Payable | 5.66M | 3.47M | 1.92M | 3.96M |
| Short Term Debt | 7.94M | 4.25M | 201.00K | 1.26M |
| Other Current Liabilities | 856.00K | 0.00 | 3.33M | 0.00 |
| Total Current Liabilities | 23.49M | 15.15M | 16.74M | 16.47M |
| Long Term Debt | 4.46M | 12.39M | 11.67M | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 2.16M | 6.73M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 4.46M | 12.40M | 13.85M | 7.53M |
| Total Liabilities | 27.95M | 27.55M | 30.59M | 24.00M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 75.07M | 14.77M | 23.48M | 24.91M |
| Common Par | 7.00K | 5.00K | 4.00K | 3.00K |
| Additional Paid In Capital | 536.28M | 413.20M | 374.53M | 338.49M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -461.22M | -398.43M | -351.05M | -313.58M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 2.00K | 3.00K | -3.00K | 0.00 |
| Total Capitalization | 79.53M | 27.16M | 35.15M | 24.91M |
| Total Equity | 75.07M | 14.77M | 23.48M | 24.91M |
| Total Liabilities & Stock Equity | 103.02M | 42.32M | 54.07M | 48.91M |
| Total Common Shares Outstanding | 68.93M | 49.54M | 42.09M | 33.98M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 59.41M | 47.20M | 40.37M | 33.89M |
| Diluted Weighted Shares Outstanding | 59.41M | 47.20M | 40.37M | 34.12M |
| Number of Employees | 124 | 122 | 112 | 127 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with SNTA
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- UserPharma
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- Userinsider buying
Latest SNTA Headlines from TheStreet
- Synta Is a Run-Up Trade Into ASCO Lung Cancer Data 05.14.13 | 10:05 am
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin 05.10.13 | 07:05 am
- Synta Pharmaceuticals Becomes Oversold (SNTA) 05.08.13 | 04:05 pm
- Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! 04.26.13 | 08:04 am
- Insiders Trading GHDX ASCMA GNC SNTA 11.15.12 | 09:11 am
- The Next Big Thing in Biotech: Cancer Drugs
09.21.12 | 07:09 am - 5 Stocks Under $10 Set to Soar 09.20.12 | 01:09 pm
- 5 Stocks Under $10 Soaring Higher 09.13.12 | 02:09 pm
- 5 Stocks With Huge Insider Buying 07.11.12 | 10:07 am
- Insiders Trading SNTA, VMW, ENSG, AFG 07.03.12 | 10:07 am
Press Releases for SNTA
- Synta Provides Company Updates And Reports Fourth Quarter And Year-End 2012 Financial Results - Business Wire 03.14.13 | 07:03 am
- Synta Announces Appointment Of Sumant Ramachandra, M.D., Ph.D. As President, Research And Development - Business Wire 03.13.13 | 04:03 pm
- Synta To Host Conference Call And Webcast Of Fourth Quarter And Year-End 2012 Financial Results On March 14, 2013 - Business Wire 02.25.13 | 07:02 am
- Synta To Present At Upcoming Conferences - Business Wire 02.11.13 | 08:02 am
- Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering - Business Wire 12.13.12 | 07:12 am
- Synta Pharmaceuticals Announces Proposed Registered Direct Offering Of Common Stock - Business Wire 12.12.12 | 04:12 pm
- Synta To Present At The Deutsche Bank 2012 DbAccess BioFEST - Business Wire 11.27.12 | 07:11 am
- Interim Results Of The Phase 2b/3 GALAXY Trial To Be Presented At The Fifth Asia Pacific Lung Cancer Conference - Business Wire 11.26.12 | 07:11 am
- Synta To Present At The Lazard Capital Markets 9th Annual Healthcare Conference - Business Wire 11.09.12 | 08:11 am
- Interim Results Of The Phase 2b GALAXY Trial To Be Presented At The Chemotherapy Foundation Symposium - Business Wire 11.07.12 | 08:11 am
Partner Headlines for SNTA
- BlackBerry Will Underperform and 4 More Analyst Notes to Looks At - Wall St. Cheat Sheet 04.01.13 | 04:04 am
- BlackBerry Will Underperform and 4 More Analyst Notes to Looks At - Wall St. Cheat Sheet 04.01.13 | 04:04 am
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Insiders Love These 3 Highly Shorted Healthcare Stocks - Seeking Alpha 01.23.13 | 09:01 am
- UPDATE: Stifel Nicolaus Initiates Synta Pharmaceuticals at Hold; Enthusiasm Outpaces Expectations - Benzinga 08.30.12 | 01:08 pm
- Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI - GuruFocus 07.07.12 | 11:07 pm
- Vertex Pharmaceuticals CRASHES 16% with 3 NASDAQ Top Percentage Losers - Wall St. Cheat Sheet 06.29.12 | 10:06 am
- Healthcare Business Recap: Orexigen RIDES Arena, Anthera IMPLODES - Wall St. Cheat Sheet 06.28.12 | 08:06 am
- Analyst Says BUY Arena and 4 Equity Insights to Analyze Now - Wall St. Cheat Sheet 06.28.12 | 03:06 am
- New Lease Agreements for Alexandria - Analyst Blog - Zacks 06.08.12 | 05:06 pm
